Use of 68Ga-DOTATOC PET/CT-enterography for Detection of the Primary Lesion in Neuroendocrine Tumors of the Small Bowel

Recruiting N/A Interventional Study
Small Bowel Neoplasia Neuroendocrine (NE) Tumors
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Diagnostic
Participants needed
18 (estimated)
Sponsor
European Institute of Oncology · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The neuroendocrine neoplasms of the small intestine (Si-NENs) is a relatively rare malignancy. Surgical resection is the only curative treatment for the early-stage. It remains controversial its application for advanced metastatic gastroenteropancreatic neuroendocrine tumours (GEP-NETs). The identification of metastatic disease and tumor grade are the most important prognostic factors in advanced…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * patients with small bowel neuroendocrine tumours * tumors with any grade (from 1 to 3) and any Ki 67 percentage * patients eligible for surgical resection Exclusion Criteria: * patients with synchronous other oncological disease * patients with Inflammatory bowel disease * p…
Contacts

Luigi Funicelli, MD

+390294372725

luigi.funicelli@ieo.it

CONTACT